The American Conference Institute’s FDA Boot Camp returns for its 38th iteration with the continued intent of providing an essential working knowledge of core FDA concepts, and real-world examples. A distinguished faculty of top FDA regulatory authorities—a “Who’s Who of the FDA Bar”—will share their knowledge and provide critical insights throughout the event’s workshops.

WilmerHale Partner Emily Whelan will lead the “Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group” workshop, building upon the content covered during the main conference on the regulatory and IP interplay in the Hatch-Waxman and Biologics Price Competition and Innovation Act schematics.